Value Picks: Uncovering Hidden Investment Gems
Value Investor’s Deep-Dive (October 15, 2025)
A research-first scan of 10 candidates, followed by a full valuation on the most compelling idea today. No hype—just numbers, drivers, and risks.
Shortlist: 10 Value Candidates Worth Attention
- Verizon (VZ)
- Why now: Healthy free cash flow (FCF) and rising 2025 guidance after network investments; dividend support looks solid. (verizon.com)
- Pfizer (PFE)
- Why now: Post-COVID reset largely digested; 2025 guidance suggests margin rebuild amid cost cuts; valuation depressed vs. history. (pfizer.com)
- Medtronic (MDT)
- Why now: Improving margin and FCF, 48th straight dividend hike, and planned diabetes separation to simplify the story. (news.medtronic.com)
- CVS Health (CVS)
- Why now: Pharmacy/benefits cash engine with managed-care headwinds being reset (premium deficiency reserve recognized). Multiple remains subdued. (investors.cvshealth.com)
- Intel (INTC)
- Why now: High-risk turnaround; 18A ramp and U.S. fab progress are real but require flawless execution and foundry wins. Deep value if it works. (barrons.com)
- Micron (MU)
- Why now: Memory upcycle and HBM demand; strong margin/FCF inflection through FY25. Cyclical—value depends on mid-cycle normalized earnings. (investors.micron.com)
- Berkshire Hathaway (BRK.B)
- Why now: Fortress balance sheet and optionality; not “cheap,” but quality at a fair price with record cash. (nasdaq.com)
- Alphabet (GOOGL)
- Why now: Low- to mid-teens P/E for a dominant franchise; capex surge weighs on near-term FCF but builds durable AI infrastructure. (cnbc.com)
- Meta (META)
- Why now: Strong FCF and engagement; capex heavy, but ROI could be high if AI bet pays. Not a classic “deep value,” more “quality compounder at a reasonable price.” (reuters.com)
- Cardinal Health (CAH)
- Why now: Durable pharma distribution economics, growing specialty exposure, improving medical profitability, and visible EPS/FCF outlook. Valuation still below peers on many metrics. (newsroom.cardinalhealth.com)
Pick: Cardinal Health (CAH)
I’m selecting Cardinal Health as the best value candidate today. It offers:
- Predictable cash flows from scale distribution
- Expanding specialty platforms (GI Alliance stake, oncology services) with higher margins
- Strengthening medical segment execution
- Clear guidance for FY26 EPS and FCF
- Still-reasonable multiples vs. direct peers McKesson and Cencora
At today’s price of $155.78, market cap ~$37B (using ~239M diluted shares guided for FY26). That sets the stage for a clean, conservative valuation. (newsroom.cardinalhealth.com)
Business Snapshot
- Core: U.S. pharma distribution (brand and specialty), plus medical products and logistics (GMPD) and “Other” (at-Home Solutions, Nuclear/Precision Health, OptiFreight).
- 2025–2026 road map: Push deeper into specialty (GI Alliance majority stake; ION), scale at-Home Solutions and logistics, drive medical profitability, and return more cash via buybacks.
- FY25/FY26 visibility:
- FY25 EPS raised to $8.05–$8.15; FY26 EPS raised to $9.30–$9.50 (13–15% growth).
- FY26 adjusted FCF targeted at $2.75–$3.25B; capex ~$600M; buybacks ~$750M.
- Shares guided: ~238–240M. (newsroom.cardinalhealth.com)
Competitive landscape: Oligopoly with McKesson and Cencora—scale, working-capital velocity, and purchasing leverage matter most. Specialty mix and services add incremental margin. GLP‑1s shift mix but flow through the channel; distributors earn pennies on the dollar of gross billings, so volume and product complexity matter more than unit price. (reuters.com)
What Can Go Wrong (Key Risks)
- Contract churn/renegotiations can ding segment profit even when revenue optics are flat.
- GLP‑1 and biosimilar dynamics can change mix; execution in medical must hold.
- Narrow margins require tight operations; small errors can matter.
- Interest expense and working-capital swings can move near-term FCF. (newsroom.cardinalhealth.com)
Valuation Deep-Dive
1) Ground-up DCF (all numbers in $ billions unless noted)
Starting point and base facts (management-guided where available):
- FY26 non-GAAP EPS: $9.40 midpoint on ~239M shares ⇒ ~$2.25B non-GAAP net income proxy.
- FY26 adjusted FCF: $2.75–$3.25B; we use $3.0B midpoint as Year 1 FCF.
- Capital intensity low; capex guided ~$0.6B; working capital generally modestly positive over a cycle. (newsroom.cardinalhealth.com)
Assumptions (explicit and conservative):
- Year 1 (FY26) FCF: $3.0B (management midpoint).
- FCF growth years 2–5: 5.0% CAGR (mix shift to specialty, execution in medical, modest buybacks).
- Years 6–10: 3.0% CAGR (matures with U.S. drug-spend growth near nominal GDP + specialty).
- Terminal growth (G): 2.0% (below nominal GDP).
- Discount rate (WACC): 8.5% base; test 8.0–9.5% in sensitivity.
- Net debt/other: Use FCF-based equity valuation; management targets ~neutral working-cap effects over cycle. (For a conservative tilt, we haircut terminal value via higher WACC in downside case.)
Step-by-step:
Years 1–5 FCF (B):
- Y1: 3.00
- Y2: 3.15
- Y3: 3.31
- Y4: 3.48
- Y5: 3.65
Years 6–10 FCF at 3% growth:
- Y6: 3.76
- Y7: 3.87
- Y8: 3.99
- Y9: 4.11
- Y10: 4.23
Terminal value at end of Y10 (Gordon): TV = FCF10 × (1+G)/(WACC–G)
- TV = 4.23 × 1.02 / (0.085 – 0.02) ≈ 4.31 / 0.065 ≈ 66.3
Present value at 8.5%:
- PV of Y1–Y10 FCF ≈ 22.9
- PV of TV ≈ 29.9
- Enterprise value (FCF to equity) ≈ 52.8
Equity per share (239M shares): ≈ $221 per share.
Sensitivity (per-share equity value):
- WACC 8.0%, G 2.0% ⇒ ~$240
- WACC 9.0%, G 1.75% ⇒ ~$200
- WACC 9.5%, G 1.5% ⇒ ~$182
DCF fair value range (rounded): $180–$240, base case ≈ $220.
Cross-check vs. guidance: The model anchors on management’s FY26 FCF midpoint and assumes mid-single-digit growth—reasonable given specialty growth and operating discipline. (newsroom.cardinalhealth.com)
2) Comparables (quick and clean)
Peers: McKesson (MCK), Cencora (COR). At today’s prices, market is granting premium multiples to the best-executing distributors; CAH trades at a discount on forward P/E using FY26 EPS ($9.30–$9.50).
- CAH forward P/E ≈ 16.4–16.8x at $155.78.
- Peer premiums reflect mix and execution, but CAH’s improving trajectory and higher FCF conversion argue for multiple convergence.
EV/FCF lens: FY26 FCF midpoint $3.0B on ~$37B market cap implies an ~8% FCF yield—attractive for an oligopoly distributor with visible growth. (newsroom.cardinalhealth.com)
Investment View
- Thesis: CAH’s distribution moat + rising specialty/services + improving medical execution = resilient and growing FCF.
- Valuation: DCF base ~$220 per share; downside (higher WACC/lower terminal) ~$180; upside with faster specialty growth or additional buybacks ~$240+.
- Margin of safety: At $155–$160, the setup offers roughly 15–40% upside to fair value, plus a modest dividend.
- What would change my mind: Major customer loss, unexpected margin compression in medical, or a reversal in specialty growth.
Bottom line: Buy for long-term value investors willing to own a steady FCF compounder with an improving mix and credible FY26 targets.
Why Other Candidates Didn’t Win Today
- Verizon: Solid FCF guidance and dividend, but secular growth is lower; upside less compelling than CAH’s rerating potential. (verizon.com)
- Pfizer: Pipeline and margin rebuild are real, but headline risk remains high; need more proof of durable non-COVID growth. (pfizer.com)
- Medtronic: Attractive, but diabetes separation execution risk and slower top-line vs. CAH’s specialty acceleration. (news.medtronic.com)
- CVS: Still resetting medical-cost trend; value is there but more moving parts. (investors.cvshealth.com)
- Intel: Big upside if foundry lands; risk/reward is more “speculative deep value” than classic value today. (barrons.com)
- Micron: Great cycle, but not a classic value at this point in the upcycle. (investors.micron.com)
- Berkshire: High quality, less mispriced. (nasdaq.com)
- Alphabet/Meta: Reasonable valuations for giants, but capex overhang and market appreciation limit “value” upside vs. CAH. (cnbc.com)
Positioning Notes
- Sizing: For a diversified value portfolio, CAH could fit as a 3–5% core position, scaled up on pullbacks toward $145 and trimmed >$210 if rerating happens quickly.
- Time horizon: 2–4 years to realize mix/medical improvements and multiple convergence.
References and Primary Sources
Cardinal Health FY25–FY26 results, guidance and segment details:
- Q4/FY25 results + FY26 guidance (EPS, FCF, capex, buybacks, shares) [newsroom.cardinalhealth.com] (newsroom.cardinalhealth.com)
- Q3 FY25 and raised FY25 outlook [newsroom.cardinalhealth.com] (newsroom.cardinalhealth.com)
- Q2 FY25 update (GI Alliance, ION acquisitions, interest outlook) [newsroom.cardinalhealth.com] (newsroom.cardinalhealth.com)
- Reuters specialty/pharma demand context [reuters.com] (reuters.com)
Market data (as of October 15, 2025):
- CAH, MCK, COR quotes [market data]
Peers and other candidates:
- Verizon 2025 guidance (EBITDA/EPS/FCF) [verizon.com] (verizon.com)
- Pfizer 2025 guidance [pfizer.com] (pfizer.com)
- Medtronic FY25 results, dividend, separation plan [news.medtronic.com] (news.medtronic.com)
- CVS Q2 2025 and premium deficiency reserve [investors.cvshealth.com] (investors.cvshealth.com)
- Intel 18A/Panther Lake progress [barrons.com; reuters.com; ft.com] (barrons.com)
- Micron FY25 trajectory and HBM [investors.micron.com; investing.com] (investors.micron.com)
- Berkshire cash/positioning [nasdaq.com] (nasdaq.com)
- Alphabet capex and AI infrastructure context [cnbc.com; fool.com] (cnbc.com)
- Meta data center expansion [reuters.com] (reuters.com)
Note: This is investment research and not investment advice. Please consider your objectives, risk tolerance, and constraints before acting.